Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab plus FOLFIRI with low‑dose irinotecan as second‑line therapy in Japanese metastatic colorectal cancer (rindo)
jRCTs041180074Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab in metastatic colorectal adenocarcinoma (mCRC) and colorectal cancer (CRC), sponsored by Eli Lilly and Company. Primary endpoint: progression-free survival. Started Jan 2018; status: completed.
02
Drugs
ramucirumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs041180074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180074.